BQ-3020

BQ-3020 is a synthetic peptide compound recognized as a potent and selective agonist of the endothelin B (ETB) receptor. Structurally derived from the endogenous endothelin peptides, it is engineered to exhibit high affinity and specificity for ETB over endothelin A (ETA) receptors, making it a valuable molecular tool for dissecting the physiological and pathophysiological roles of endothelin signaling pathways. Its utility extends across cardiovascular, neurobiological, and renal research, where precise modulation of ETB receptor activity is essential for understanding complex regulatory mechanisms. As a research-use-only reagent, BQ-3020 offers a robust platform for advancing knowledge in receptor pharmacology and cellular signaling.

Receptor Pharmacology Studies: BQ-3020 is widely employed in receptor binding assays and functional studies to elucidate the pharmacological properties of the ETB receptor. By selectively activating ETB, researchers can differentiate the downstream effects mediated by this receptor subtype from those triggered by ETA, facilitating the mapping of endothelin receptor distribution and function in various tissues. Such investigations are critical for advancing the understanding of endothelin system dynamics in both normal physiology and disease models.

Signal Transduction Analysis: The compound serves as a precise probe for exploring intracellular signaling cascades initiated by ETB receptor activation. In cell-based assays, it enables the characterization of second messenger systems, such as calcium mobilization, nitric oxide production, and kinase activation, following receptor engagement. These studies provide insights into the molecular mechanisms governing endothelial function, smooth muscle relaxation, and neurotransmission, thereby supporting the development of new hypotheses in vascular and neural biology.

Vascular Function Research: BQ-3020 is frequently utilized in ex vivo and in vitro models to investigate the role of ETB receptors in vascular tone regulation. By selectively stimulating ETB, it aids in delineating the contributions of endothelium-derived relaxing factors and the mechanisms underlying vasodilation versus vasoconstriction. This application is especially relevant for studies focused on hypertension, atherosclerosis, and other cardiovascular disorders where endothelin signaling is implicated.

Renal Physiology Investigations: In kidney research, the peptide is used to probe the involvement of ETB receptors in modulating renal blood flow, sodium excretion, and glomerular filtration. Its selective action allows researchers to distinguish ETB-mediated effects from those of ETA, supporting the identification of receptor-specific pathways in renal homeostasis. These insights are instrumental for advancing the understanding of fluid and electrolyte balance as well as the pathogenesis of renal diseases.

Neuroscience and Neuroprotection Studies: BQ-3020 has found application in neurobiological research aimed at elucidating the function of ETB receptors in the central and peripheral nervous systems. By activating ETB, it enables the study of neuropeptide signaling, neural plasticity, and potential neuroprotective mechanisms. Experimental models employing this compound contribute to the broader comprehension of endothelin's influence on neuronal survival, neurotransmitter release, and neurovascular coupling, thereby informing future directions in neuropharmacology.

1. Tachykinin-related peptides modulate immune-gene expression in the mealworm beetle Tenebrio molitor L

2. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists

3. Immune responses to peptides containing homocitrulline or citrulline in the DR4-transgenic mouse model of rheumatoid arthritis

4. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

5. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry